Investigational drug · Phase 2
HEC53856
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chemotherapy-induced Anemia, Non-Myeloid Malignancy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HEC53856"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HEC53856", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy-induced Anemia
- Non-Myeloid Malignancy
Approved drugs for the same conditions: Anemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HEC53856" as an intervention, largest first.
- HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid MalignanciesPivotal-lookingNot yet recruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07891377 · 160 participants (planned) · Start Dec 2026 · Primary completion Feb 2028
Drug: HEC53856 tablet; rHuEPO injection · For: Chemotherapy-induced Anemia; Non-Myeloid Malignancy
Sites: Shanghai, China
- HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy VolunteersPivotal-lookingCompleted
Sunshine Lake Pharma Co., Ltd.Industry
NCT03886688 · 116 participants · Start May 14, 2019 · Primary completion Jan 1, 2020
Drug: HEC53856; placebo · For: Healthy
Sites: Changchun, China
- Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.Completed
Sunshine Lake Pharma Co., Ltd.Industry
NCT04925674 · 60 participants · Start Sep 10, 2021 · Primary completion Oct 19, 2022
Drug: HEC53856 · For: Hemodialysis; Peritoneal Dialysis
Sites: Guangzhou, China; Chengdu, China; Shantou, China · 7 sites in all
Sunshine Lake Pharma Co., Ltd.Industry
NCT04925661 · 40 participants · Start Nov 4, 2021 · Primary completion Aug 29, 2023
Drug: HEC53856; Roxadustat and 1 more · For: Chronic Kidney Diseases; Renal Anemia
Sites: Guangzhou, China; Hangzhou, China; Nanning, China · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chemotherapy-induced Anemia
- SSS06Phase 21 trial
Shenyang Sunshine Pharmaceutical Co., LTD. · Chemotherapy-induced Anemia, Non-myeloid Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.